8results about How to "Low cross-reactivity" patented technology

The invention belongs to the technical field of molecular biology, and particularly discloses a theophylline aptamer and a virtual screening method and application thereof. The theophylline aptamer is selected from one or more of MUT9, MUT16, MUT67, MUT78 or MUT89. The invention further discloses a preparation method of the theophylline aptamer. The invention discloses a theophylline aptamer as well as a virtual screening method and application thereof, the theophylline aptamer is high in affinity and specificity, the virtual screening method remarkably improves the accuracy and efficiency of virtual screening, the theophylline aptamer can be quickly obtained at low cost, and a powerful calculation tool is provided for rational design and application of the aptamer.

This invention discloses chloramphenicol hapten, antigen, antibody, colloidal gold detection device, and their preparation methods and applications. The chloramphenicol hapten prepared by this invention using a total synthesis method retains all potential recognition sites of chloramphenicol to the maximum extent, and in particular, for the first time retains the most critical dichloro structure of chloramphenicol. After introducing a spacer arm, its electron cloud distribution is almost identical to the overall electron cloud distribution of chloramphenicol, improving the immunogenicity of the chloramphenicol antigen. The chloramphenicol antigen and monoclonal antibody prepared by this invention have high specificity for ELISA detection, with an IC50 value of [missing information]. 50 The value was 8.21 pg / mL, the linear detection range was 1.71–39.45 pg / mL, the cross-reactivity to common structural analogs was less than 0.01%, and the sensitivity to chloramphenicol in the sample was 0.1 µg / kg.

The application relates to a monoclonal antibody of alpha, beta and gamma amatoxin and a preparation method and application thereof. The monoclonal antibody of alpha amatoxin is prepared from an alpha amatoxin artificial antigen, the monoclonal antibody of beta amatoxin is prepared from a beta amatoxin artificial antigen, and the monoclonal antibody of gamma amatoxin is prepared from a gamma amatoxin artificial antigen; the alpha amatoxin artificial antigen is a conjugate of alpha amatoxin and keyhole limpet hemocyanin, the beta amatoxin artificial antigen is a conjugate of beta amatoxin and bovine serum albumin, and the gamma amatoxin artificial antigen is a conjugate of gamma amatoxin and human serum albumin. The three antibodies have a small cross-reaction rate, can simultaneously detect and distinguish alpha-AMA, beta-AMA and gamma-AMA in a sample, and have high accuracy.

This invention discloses a recombinant protein of Coxsackievirus B3 type 3C protease, a polyclonal antibody, and their preparation method and applications. Based on the CVB3 genome sequence, full-length primers were designed, and the 3C fragment was obtained by PCR amplification. The pET28a-3C recombinant expression vector was constructed, transformed into competent bacteria, and induced to express by IPTG. The CVB3 3C protease recombinant protein was then purified. Using this recombinant protein as an immunogen, it was emulsified with Freund's adjuvant and used to immunize animals. After multiple immunizations, serum was collected to obtain the CVB3 3C protein polyclonal antibody. The prepared polyclonal antibody exhibits high specificity, specifically recognizing the 3C protein band at 28 kDa. It can be widely applied in detection methods such as Western blot, immunofluorescence, and immunoprecipitation for the expression analysis, intracellular localization study, and screening of interacting proteins of the 3C protein during CVB3 infection.

The application discloses a method for improving the sensitivity of RPA-CRISPR-Cas12a detection and application thereof in one-tube detection of chikungunya virus, and relates to the technical field of biology.The full-length crRNA is reformed to form a truncated crRNA (Truncate crRNA), the non-key region is accurately shortened, the space-time regulation of Cas protein activity is realized, and the truncated crRNA plays a key role in CRISPR molecular detection (such as an RPA-CRISPR-Cas12a system). The method can significantly improve the specificity of RPA-CRISPR-Cas12a detection, effectively avoid cross-reaction, inhibit non-specific early activation, significantly reduce background signals, and provide an optimization strategy for developing a molecular diagnostic technology with higher sensitivity.

The present application relates to the technical field of nanobody, in particular to anti-FcRH5 nanobody and its application. The present application provides a kind of anti-FcRH5 nanobody with high affinity and specificity, which is based on the single domain heavy chain variable region structure of camelid origin, with the advantages of small molecular weight, high stability, strong tissue penetration, easy to be engineered and the like. The nanobody specifically recognizes and binds to the target point highly expressed and stably expressed on the surface of multiple myeloma cells through its complementarity determining region. The nanobody of the present application can be used as a core recognition element to construct a variety of therapeutic or diagnostic tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes. The technical scheme can solve the technical problem that there is a lack of high-quality, functionally clear anti-FcRH5 antibody in the prior art. The nanobody of the present application has significant clinical transformation and industrialization advantages, and promotes the treatment of multiple myeloma to multiple target points.

The application belongs to the technical field of biological medicine, and provides a mouse anti-human PRCC monoclonal paired antibody, a hybridoma cell strain and application thereof. The application provides hybridoma cell strains 5F9C2 (CCTCC NO: C2025312) and 15F7B5 (CCTCC NO: C2025341) which respectively secrete antibodies with unique heavy chain / light chain variable regions; the antibodies can be used for immunohistochemical and immunoblotting detection of PRCC alone, and can also be paired to establish a sandwich method system through an enzyme-linked immunosorbent assay. The antibodies provided by the application are high in specificity and sensitivity, and can be used for accurate qualitative and quantitative analysis of PRCC.

This invention discloses a semi-quantitative RT-LAMP method and kit for viral nucleic acid detection based on dispensed lyophilized microspheres and a multi-channel microfluidic chip. The method includes: designing two independent LAMP primer sets (P1 and P2) for each of the SARS-CoV-2 Omicron strain N gene, Zika virus NS5 gene, H1N1 influenza virus M1 gene, and H3N2 influenza virus NP gene; preparing two independent types of lyophilized microspheres by independently mixing RT-LAMP premix containing Bst DNA polymerase and other components with LAMP primer mixture and a lyophilization protectant; and using an N-channel microfluidic chip to perform serial dilutions and parallel RT-LAMP amplification of the same sample, determining the concentration of viral nucleic acid in the sample by the positive / negative inflection points of each channel. This invention is simple to operate, requires no equipment such as a real-time PCR instrument, and is suitable for rapid virus detection in various scenarios.